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REAMBLE
he American College of Cardiology (ACC) and the
merican Heart Association (AHA) recognize the im-
ortance of refining the lexicon used to describe the
rocess and outcomes of clinical care, whether in ran-
omized trials, observational studies, registries, or quality
mprovement initiatives. Broad professional agreement
n a common vocabulary with common definitions will
acilitate cross-study comparisons or, when advantageous,
ombining of data across studies and improving the
ssessment of any project’s generalizability to clinical
ractice. To further efforts aimed at standardizing such a
exicon, the ACC and AHA have undertaken to develop
nd publish clinical data standards—sets of standardized
ata elements and corresponding definitions that can be
sed in a variety of data collection efforts for a range of
ardiovascular conditions.
It is hoped that these clinical data standards will:
. Improve cross-comparison of results and clinical out-
comes between different trials and registries.
. Facilitate the development and conduct of future regis-
tries, at both hospital and national levels, by providing a
list of major variables, outcomes, and definitions.
. Facilitate measurement for quality improvement pro-
grams.
. Become the basis for a standardized medical documen-
tation process with the anticipation that the medical
record will progress to an electronic format.
The ACC/AHA Task Force on Clinical Data Stan-
ards makes every effort to avoid any actual or potential
onflicts of interest that might arise as a result of an hutside relationship or a personal interest of a member of
he writing panel. Specifically, all members of the writing
anel are asked to provide disclosure statements of all
uch relationships that might be perceived as real or
otential conflicts of interest. These statements are re-
iewed by the parent task force, reported orally to all
embers of the writing panel at the first meeting, and
pdated as changes occur.
The ACC/AHA Task Force on Clinical Data Stan-
ards selects cardiovascular conditions and procedures
hat would benefit from the creation of a standard
ataset. Experts in the subject are selected to examine/
onsider existing data standards and develop a compre-
ensive, yet not exhaustive, standard dataset. Users
hould understand that, when undertaking a data collec-
ion effort, only a subset may be needed or, conversely,
hey may want to consider whether it may be necessary to
ollect some elements not listed. For example, in the
etting of a randomized clinical trial of a new drug,
dditional information would likely be required regarding
tudy procedures and drug therapies.
The ACC and AHA aim to standardize the language
sed to describe cardiovascular diseases and procedures,
nhance consistency in cardiology, and increase opportu-
ities for sharing data across various data sources. The
ltimate goal of ACC/AHA clinical data standards is to
ontribute to the infrastructure necessary for accomplish-
ng the ACC/AHA’s mission of fostering optimal car-
iovascular care and disease prevention.
The ACC and AHA support the goals of their
embers to improve cardiovascular care and disease
revention through professional education, promotion of
esearch, development of guidelines and standards for
ardiovascular care, and fostering a policy that supports
ptimal patient outcomes. Both the ACC and the AHA
ecognize the importance of the use of clinical data for
atient management, in the assessment of patient out-
omes, and in research efforts focused on improving the
linical treatment of patients.
As a component of this objective, the ACC/AHA
linical data standards concentrate on the identification,
efinition, and standardization of data corresponding
ith various clinical topics in cardiology. The primary
oal of clinical data standards is to assist in the collection
f data by providing an initial platform of data elements
nd corresponding definitions applicable to various dis-
ase conditions in cardiology. These key elements and
efinitions are a compilation of variables applicable in the
easurement of patient clinical management and out-
omes, and for research and epidemiological assessments.
The Health Insurance Portability and Accountability
ct (HIPAA) privacy regulations, which went into effect
n April 2003, have heightened all practitioners’ aware-
ess of our professional commitment to safeguard our
atients’ privacy. Our goal is to treat every patient’s
ealth information with the same respect and courtesy as
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ww.hhs.gov/ocr/combinedregtext.pdf, page 31) specify
hich elements are considered “protected health infor-
ation.” These elements may not be disclosed to third
arties (including registries and research studies) without
he patient’s written permission. Protected health infor-
ation may be included in databases used for health care
perations under a data use agreement. Research studies
sing protected health information must be reviewed by
n Institutional Review Board or a Privacy Board.
We have included identifying information in all clin-
cal data standards, to facilitate uniform collection of
hese elements when appropriate. For example, a longi-
udinal clinic database may contain these elements, be-
ause access is restricted to the patient’s caregivers.
onversely, registries may not contain protected health
nformation, unless specific permission is granted by each
atient. These fields are indicated as protected health
nformation (PHI) in the data standards.
Our understanding of the importance of data element
tandardization, the backbone of clinical care, clinical
esearch, and quality performance measurement, derives
rom experience with clinical care, clinical research, and
uality performance measurement. In clinical care, care-
ivers communicate with each other through a common
ocabulary. The integrity of clinical research depends in
arge part on firm adherence to prespecified procedures
or patient enrollment and follow-up; these procedures
re guaranteed through careful attention to definitions
numerated in the study design and case report forms.
hen data elements and definitions are standardized
cross studies, comparisons, pooled analyses, and meta-
nalyses are enabled, thus deepening our understanding
f individual clinical trials.
The recent development of quality performance mea-
urement initiatives, particularly those for which compar-
son of providers is an implicit or explicit aim, has further
aised awareness among the professional community
bout the importance of data standards. For the first
ime, a wide audience, including non-medical profession-
ls such as payers, regulators, and consumers, may draw
onclusions about care and outcomes. For understanding
nd comparison of care patterns and outcomes to be fair,
he data elements that comprise the descriptions of these
atterns and outcomes of care must be clearly defined,
onsistently used, and properly interpreted by a broader
udience than ever before.
Paul A. Heidenreich, MD, MS, FACC
Chair, ACC/AHA Task Force on Clinical Data Standards
. INTRODUCTION
he syndrome of heart failure (HF) is a common manifes-
ation of the later stages of various cardiovascular diseases,
ncluding coronary artery disease, hypertension, valvular
isease, and primary myocardial disease. It is the most wommon reason for hospitalization among older individuals
1), and its appearance usually foreshadows the need for
ngoing care for the duration of the patient’s life. Therapy
or HF has benefited from scientific investigations into basic
olecular mechanisms of disease (2,3) from advances in
ngineering, instrumentation, and surgery (4) and from
arge multicenter trials (5–7) and registries (8,9). Increas-
ngly, care of patients with HF, particularly advanced HF,
ay take place in specialized clinics using a team approach
10–12). In addition, growing national interest in quality of
reatment has focused scrutiny on patterns and outcomes of
F care (13,14).
Heart failure was identified for development of data
tandards by the ACC and the AHA. As with the first
ondition, acute coronary syndromes (ACS) (15), and the
econd condition, atrial fibrillation (AF) (16), the goal of
he data standards is to provide a standardized informa-
ion platform that will be useful in a variety of situations,
articularly clinical trials, clinical registries, and quality
erformance measurement. Similar to the writing com-
ittees for ACS and AF clinical data standards, the
CC/AHA Writing Committee to Develop Clinical
ata Standards for Heart Failure proceeded to develop
ata element definitions with the understanding that they
ight be useful in a variety of circumstances:
Clinical programs, such as HF clinics, where many
providers work together to achieve specific and specified
goals for the care of patients with HF.
Clinical registries, for ongoing care, prospective epide-
miologic research, or prospective quality performance
measurement.
Clinical research, particularly prospective randomized
clinical trials where eventual pooled analysis or meta-
analysis is anticipated.
Quality performance measurement initiatives, provider-
based or external, retrospective or prospective.
Organization and design of electronic medical informa-
tion initiatives, such as electronic medical records, phar-
macy databases, or computerized decision support.
I. METHODOLOGY
. Writing Committee Composition
he ACC/AHA Task Force on Clinical Data Standards
elected members for the ACC/AHA Writing Commit-
ee to Develop Clinical Data Standards for Heart Failure
Writing Committee). The Writing Committee con-
isted of 10 members who are active in clinical research in
F, clinical programs (HF clinics, transplant programs,
enters of excellence), HF registries, and quality perfor-
ance measurement initiatives. The Writing Committee
ncluded membership from the U.S., Great Britain, and
anada so as to ensure balance in the selection of data
lements and consideration of variations in practice
orldwide. A representative from cardiovascular nursing
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nsure consistency between the clinical data standards
nd other ACC/AHA HF documents, the Task Force
lso appointed representatives from the ACC/AHA
eart Failure Guideline Update Writing Committee and
he ACC/AHA Heart Failure Performance Measures
riting Committee.
. Relationships With Industry
he American College of Cardiology makes every effort
o avoid any actual or potential conflicts of interest that
ay arise as a result of an outside relationship or a
ersonal, professional, or business interest of a member of
he writing panel. Specifically, all members of the writing
roup are required to complete and submit a disclosure
orm showing all such relationships that might be per-
eived as real or potential conflicts of interest. These
tatements are reviewed by the ACC/AHA Task Force
n Clinical Data Standards, reported orally to all mem-
ers of the writing panel at the first meeting, and updated
s changes occur. Please see Appendix B for Writing
ommittee relationships with industry and Appendix C
or relationships with industry information for peer
eviewers of this document.
. Review of the Literature
nd Existing Data Definitions
he ACC/AHA Task Force on Clinical Data Standards
upported gathering as many candidate data elements and
efinitions as possible, principally from large clinical trials,
ational quality performance measurement initiatives, and
uidelines. The Writing Committee compiled and reviewed
ase report forms, data elements, and definitions from
ational, international, and local cardiovascular data col-
ection efforts. Examples of these data sources include
he ACC-NCDR (http://www.accncdr.com/WebNCDR/
lements.aspx), the ACC Key Data Elements and Defini-
ions for Measuring the Clinical Management and Out-
omes of Patients With Acute Coronary Syndromes (15),
he Quality Indicators for Heart Failure Patients (http://
ms.hhs.gov/healthplans/chf/qapi-0601.pdf), the Cardiac
ransplant Research Database, Centers for Disease Control
nd Prevention Common Data Elements (http://
ww.cdc.gov/data/impv24.pdf), the Iowa Foundation for
edical Care’s Heart Failure tools (http://www.
nternetifmc.com/prof_inpatient_hf_tools.php), and the
rganized Program to Initiate Life-Saving Treatment in
ospitalized Patients with Heart Failure (OPTIMIZE-
F) Internet-based registry (17).
The HF data standards are meant to provide data
lements that parallel and complement other ACC and
HA standards, specifically the guidelines and the per-
ormance measures. The ACC/AHA 2005 Guideline
pdate for the Diagnosis and Management of Chronic
eart Failure in the Adult (18) served as the primary
vidence-based document that writers of this data ele- oent set referenced in their development of data element
efinitions. The ACC/AHA Clinical Performance Mea-
ures for Adults With Chronic Heart Failure (19) were
eveloped simultaneously with the HF data standards,
ith frequent exchange of information between these two
ommittees. Other research articles, clinical trials, and
eference sources were consulted as needed and are cited
hroughout this document.
. Prioritizing Data Elements
fter the Writing Committee reviewed the HF guide-
ines, other pertinent literature, and the data definitions
rom related sources, a comprehensive list of possible data
lements to include in this set was created. This initial list
imed at capturing the universe of potential elements
ith the understanding that, by necessity, this set of data
lements must be limited to those elements most likely to
e needed in data collection efforts for research, clinical
are, and quality improvement. From this initial list, the
riting Committee graded the importance of including
ach data element as “high,” “medium,” or “low.” All of
he data elements with an average “high” score and the
ajority of those with an average “medium” score were
aintained in the set. The rest of the elements were not
efined at this time, but they are maintained as possible
lements to be defined and added at a later time.
The process of writing and revising data element
efinitions caused many data elements to move in or out
f the set for a variety of reasons. In some instances, an
lement that on its own may have been ranked “low” was
ecessary to complete a subset of elements pertaining to
related concept. Conversely, an element that was ranked
s “high” may later have been determined to be impos-
ible to define in a manner that facilitates consistent data
ollection, or its content may have been determined to be
ontained within another data element. In this fashion,
he process of prioritizing, adding, and removing data
lements continued throughout the Writing Committee’s
rocess.
. Defining Data Elements
embers of the Writing Committee drafted definitions
or those data elements deemed to have priority for the
rst publication of the HF data standards. Each writer
eceived a template to assist in drafting the definitions
nd to provide for a structured format across authors.
embers were encouraged to write definitions broad
nough to be applicable in a variety of data collection
ettings, but specific enough that the data elements can
e uniformly interpreted. Data elements have also been
efined to be usable in both inpatient and outpatient
ettings.
Writing team members received sample definitions
rom a variety of existing sources (see Section “C. Review
f the Literature and Existing Data Definitions”). Data
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vidence-based national guidelines, specifically the ACC/
HA 2005 HF Guideline Update (18). To ensure
onsistency across ACC/AHA clinical data standards,
riters were instructed to use an existing ACC/AHA
efinition verbatim unless there was a reason related to
F to change that definition.
Similar to guidelines and performance measures, data
tandards require regular review and updating. At the
nniversary of the data standards publication, the Writ-
ng Committee chair, in conjunction with Writing Com-
ittee members, will review the data standards to ascer-
ain whether or not modifications should be considered.
ublished ACC/AHA practice guidelines are reviewed
ne year after publication to determine whether signifi-
ant advances have occurred in clinical practice to warrant
hanges in recommendations. To keep current, whenever
he relevant guideline is updated the associated data
tandards will be reviewed and revised to reflect those
hanges.
. Consensus Development
he ACC/AHA data standards are consensus, team-
ritten documents that are based on judgments of experts
n the field of cardiology. This Writing Committee met
everal times, both in person and through conference
alls, over the course of several months to define and
efine the data elements. Throughout the creation of the
ata element set, consensus was developed through dis-
ussions (either during face-to-face meetings or confer-
nce calls), e-mails, and sometimes written votes. The
rocess of consensus development allowed for the incor-
oration of minority opinions in the few instances when
group consensus could not be achieved.
. Peer Review, Public Comment, and Board Approval
he set of HF data elements was independently reviewed
y three official reviewers nominated by the ACC and
wo official reviewers nominated by the AHA, the ACC/
HA Heart Failure Guideline Update Writing Commit-
ee chair, the ACC/AHA Task Force on Clinical Data
tandards, and four independent content reviewers. To
urther increase its applicability, the document was
osted on the ACC Web site (www.acc.org) for a 30-day
ublic comment period. The document was approved for
ublication by the governing bodies of the American
ollege of Cardiology and the American Heart Associ-
tion. The document has been formally endorsed by the
eart Failure Society of America (HFSA). To determine
hether a revision is necessary, these clinical data stan-
ards will be reviewed a year after publication and yearly
hereafter by the ACC/AHA Task Force on Clinical
ata Standards. e. Considerations for Use of
ata Elements and Definitions
lthough the ACC/AHA is not launching this set of
ata element definitions as the precursor to a national
egistry, it recognizes that definitions cannot be written
ffectively without the context of their intended use. The
riting Committee determined three major environ-
ents of data collection efforts:
. Clinical research
. Clinical care
. Quality performance measurement
he needs of clinical researchers are frequently unique to
he specific research objective. This necessitates specific
ata element design and definitions, and the definitions
roposed in this document may be considered as a
tarting point. In contrast, quality performance measure-
ent, particularly when quality comparison is the goal,
equires standard definitions for all data elements. When
aregivers anticipate outcomes research based on their
atients’ care and experiences, uniform definitions are
lso strongly advised. Discussion of the considerations for
se in clinical care and quality performance measurement
as as much a component of the consensus development
rocess as were the data definitions themselves.
It should be noted that clinical data standards present a
odel of elements that might be employed in data collec-
ion efforts, such as operating a registry, and are not
unctional databases in themselves.
. Special Considerations and
hallenges for HF Data Standards
everal special considerations were raised by the Writing
ommittee in its deliberations about which data ele-
ents to include and how to define them.
. Uses for HF data standards. In considering heart
ailure data elements, their importance and their use for
pecific goals need to be borne in mind. For clinical care,
lements pertaining to patient assessment and medical
ecision-making are paramount. For clinical research,
lements pertaining to patient classification and out-
omes are most important. For quality performance
easurement, elements pertaining to care patterns and
atient characteristics modulating care patterns take pre-
edence. For example, for a clinician following a patient
ith HF, specific physical examination findings that
ictate alterations in management are more important to
etermine than even the eventual outcome, whereas for
linical research the importance of these data elements is
eversed. For quality performance measurement, ele-
ents describing the health care provider’s decision-
aking (what the provider did and why) are important to
lucidate.
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Chronic Heart Failure in the Adult: ACC/AHA Clinical Data Standards September 20, 2005:1179–207. Balance between focus and comprehensiveness. Al-
hough it may be tempting to develop a very comprehen-
ive data element catalogue encompassing every imagin-
ble data need or use, the Writing Committee focused on
ommonly collected data elements to best focus and
nable the use of these data elements in many situations
y many users. In particular, the Writing Committee
ocused on the care of adults with HF. We acknowledge
hat congenital heart disease may be accompanied by HF,
ut have proceeded with the understanding that data
lements specific to these conditions can be added at a
ater time or can be incorporated into a similar data
tandards effort directed toward congenital heart disease.
. Balance between “primary” and “summary” data
lements. In the process of diagnosis and treatment,
linicians gather detailed clinical information, synthesiz-
ng the details into a formulation and plan for each
atient. It follows, then, that data elements making up a
linical dataset may consist of many individual data
lements (e.g., the details of coronary anatomy assessed
y angiography) or of summary concepts (e.g., the num-
er of diseased coronary vessels or the physician’s assess-
ent that coronary artery disease is or is not a contrib-
ting factor to the patient’s HF syndrome). More often
han not, the committee emphasized primary data ele-
ents for those features characterizing the HF syndrome
nd summary data elements for etiologic and therapeutic
haracteristics. It was recognized, however, that specific
rojects involving, for example, a diagnostic test or a
herapeutic technique, would amplify these core, sum-
ary measures with a richer vocabulary of primary data
lements.
. Variety of disease states leading to HF. Heart failure
s a syndrome, not a disease. It is a physiologic state
esulting from a variety of disease conditions and clinical
ituations including coronary artery disease, hyperten-
ion, valvular disease, hypertension, infection, cancer
hemotherapy, and more. Given the Writing Commit-
ee’s focus on data elements pertaining to the HF
yndrome and its care, the data elements contained herein
ill be most useful for data collection efforts directed
oward patients in Stage C or Stage D heart failure as
efined by the ACC/AHA 2005 HF Guideline Update
taging classification scheme (18).
. Acute and chronic care, inpatient and outpatient care
enues. In contrast to acute coronary syndromes, HF is a
hronic condition, usually with acute manifestations and
xacerbations. Clinical care and clinical research are, in
eneral, oriented toward gathering information prospec-
ively about chronic outpatient-based care, whereas most
uality performance measurement efforts are directed
oward acute care received during hospitalization, usually
athered retrospectively. The Writing Committee con- pidered data elements pertinent to the full range of acute
nd chronic care provided to these patients. The data
lements are intended to be useful for both inpatient and
utpatient care venues.
. Therapy for HF. Defining data elements to describe
herapy for HF is a particular challenge. The Writing
ommittee recognizes that for clinical care, detailed
nformation about therapy is essential. Other uses for
hese data elements require a summary approach. Given
he variety of potential uses of these data standards, the
riting Committee recommends collecting information
bout medications as total daily dose prescribed at out-
atient encounters or upon discharge from acute care
ospitalization, and as summary information for thera-
eutic procedures such as coronary revascularization de-
ice implantation. Specific registries and clinical trials of
reatment would be expected to specify additional data
lements to supplement the summary elements outlined
n this document.
. Outcomes assessment for HF. Mortality and hospi-
alization outcomes are more comparable and under-
tandable when adjusted for risk; current understanding
f important risk-adjustment domains for these outcomes
as informed the inclusion of specific data elements. In
ddition, because HF is a chronic condition, HF care also
ncompasses outcomes such as symptom burden, func-
ional status, psychological state, compliance with a
herapeutic regimen, self-management, and quality of life
11,20–23). (Please see Appendix A for a more detailed
iscussion of assessment and interpretation.)
II. HF CLINICAL DATA STANDARD
LEMENTS AND DEFINITIONS
. Patient Demographics (Table 1)
atient demographic information is used for patient
dentification for longitudinal care, for demographic
rouping to assess issues of access and care quality for
raditionally disadvantaged groups, and for risk adjust-
ent. Association of any health information with unique
atient identifiers and/or demographic information that
an be linked to the individual patient (indicated by an
sterisk in Table 1) identifies the dataset as “protected
ealth information.” Unique patient identification infor-
ation (Social Security number or medical record num-
er) is necessary and appropriate for longitudinal clinical
are, but given current legislation protecting patients’
rivacy (24), such information is not included in multi-
nstitution registries unless appropriate informed consent
s obtained from all patients. For other uses, patient
rivacy concerns may need to be considered by hospital
rivacy officers and/or institutional review boards (IRBs).
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Data Element Definition
Gender Indicate the patient’s gender at birth. Choose one of the following:
● Male
● Female
Date of birth Patient date of birth (day, month, and year of patient’s birth).
Hispanic ethnicity Is this patient Spanish, Hispanic, or Latino? Choose one of the following:
● Yes
● No
Race Patient’s race as determined by the patient/family:
● American Indian or Alaska Native
● Asian
● Black or African American
● Native Hawaiian or other Pacific Islander
● White
● Other (specify)
Patient zip code Zip code where the patient typically resides.
Care period For inpatient, note the date the patient was admitted to the hospital and the date the patient was discharged from
the hospital.
For outpatient, note the date (day, month, year) of the encounter (physician visit, nurse visit, consultation,
procedures, and so on).
nsurance payor Indicate the patient’s primary insurance payor for this admission. Choose one of the following:
● Government: Refers to patients who are covered by government-reimbursed care. In the U.S., this
includes:
- Medicare
- Medicaid (including all state or federal Medicaid-type programs)
- Champus
- Veterans Health Administration
- Department of Defense
- Other federal group (specify)
● Commercial: refers to all indemnity (fee-for-service) carriers and preferred provider organizations (PPOs).
● HMO: refers to a health maintenance organization characterized by coverage that provides health care services
for members on a pre-paid basis.
● None: refers to individuals with no or limited health insurance; thus, the individual is the payor regardless of
ability to pay. Only mark “None” when “self” or “none” is denoted as the first insurance in the medical record.
overnment payor type If the patient’s primary insurance payor for this encounter is “Government,” choose the type of government
insurance:
● Medicare
● Medicaid
● Other
resentation to health care
acility
Type of presentation to health care facility:
● Emergency admission for HF
● Emergency admission for other cardiovascular problem
● Emergency admission for non-cardiovascular problem (e.g., pneumonia)
● Planned admission for cardiovascular disease
● Planned admission for non-cardiovascular disease
● Regularly scheduled outpatient visit
● Other outpatient visits, including urgent outpatient visits
● Remote monitoring
● Telephone contact
● Electronic communication
● Other (specify)
Note if patient is a new patient or a prior patient with a new entry.
ocation of health care
ncounter
Type of location of health care encounter:
● Acute-care hospital
● Long-term care facility
● Emergency department
● Caregiver office
- Heart failure clinic
- Cardiology practice
- Primary care physician office
- Other caregiver office● Other (specify)
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nformation about patients’ medical history is important in
uality performance measurement, clinical research, and clin-
cal care. Presence of cardiac risk factors have both prognostic
nd management implications, as do elements describing
urrent cardiovascular conditions. History of non-cardiac con-
itions may denote absolute or relative contraindications to
arious therapies, or may significantly impact outcomes. Inclu-
ion of data elements pertinent to medical history is, therefore,
able 1 Continued
Data Element
isposition after health care
ncounter
Indicate disposition after health
● Discharged to home or self c
● Discharged/transferred to an
● Discharged/transferred to sk
● Discharged/transferred to an
● Discharged/transferred to an
● Discharged/transferred to ho
● Left against medical advice o
● Discharged/transferred to ho
● Admitted as an inpatient to
● Expired (or did not recover)
● Hospice-home
● Hospice-medical facility
● Discharged/transferred to an
hospital
Specify date.
eath Specify date of death. Indicate c
● Cardiovascular:
- Myocardial infarction
- Cardiogenic shock
- Heart failure
- Sudden cardiac death
- Cardiac arrest
- Arrhythmia (specify)
- Stroke
- Other (specify)
● Non-cardiovascular:
- Pulmonary emobolism
- Cancer
- Trauma
- Sepsis
- Chronic obstructive lung
- Renal failure
- Other (specify)
Indicate location of death, if kno
● At home
● In hospice care
● In hospital
● Other (specify)For current or former smokers, tomportant to clinical decision-making, to design of quality
erformance measures, and to risk-adjusted outcomes assess-
ent. For most purposes, these data elements can be recorded
s either present or absent. Year of onset may be helpful,
specially when data collection is used for longitudinal clinical
ollow-up. More detailed information about the severity of
ach condition (e.g., record of prior hospitalizations or specifics
f therapy for the condition) might be considered for certain
sers.
Definition
ncounter:
outine discharge)
short-term general hospital for inpatient care
ursing facility (SNF)
mediate care facility (ICF)
type of institution
nder care of organized home health service organization
ontinued care
nder care of a home IV drug therapy provider
ospital
ient rehabilitation facility including rehabilitation distinct part units of a
f death, if available:
eable 2. Medical History
Data Element Definition
edical History: Heart Failure Risk Factors
istory of smoking History confirming cigarette smoking in the past. Choose from the following categories:
● Current: smoking cigarettes within one month of this encounter
● Recent: stopped smoking cigarettes between 1 month and 1 year before this encounter
● Former: stopped smoking cigarettes more than one year prior to this encounter
● Never: never smoked cigarettescare e
are (r
other
illed n
inter
other
me u
r disc
me u
this h
inpat
ause o
diseas
wn:tal pack years may be useful.
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Data Element Definition
edical History: Heart Failure Risk Factors, continued
istory of alcohol consumption/
ependency
Alcohol consumption history. Choose from the following categories:
● None
● One or fewer alcoholic drinks per week
● 2 to 7 alcoholic drinks per week
● 8 or more alcoholic drinks per week
Alcohol dependency history:
● Documented alcohol dependency
● Medical sequelae of alcohol consumption (alcoholic hepatitis, cirrhosis, alcohol neuropathy,
Wernicke-Korsakoff syndrome)
● Treatment for alcohol dependency
For dependent consumers of alcohol, note treatment for dependency, cessation of use, or continued use.
istory of diabetes History of diabetes, regardless of duration of disease, need for antidiabetic agents, or a fasting blood sugar
greater than 7 mmol/l or 126 mg/dl.
The year of onset (first diagnosis) and whether juvenile or adult onset may be helpful.
iabetes treatment Method of diabetic treatment at time of encounter. Choose from the following categories:
● None: no treatment for diabetes
● Diet: diet treatment
● Oral: oral agent treatment. Oral agent(s) should be specified:
- Metformin
- Sulfonylureas
- Thiazolidinediones (TZDs)
● Insulin: insulin treatment
● Insulin and oral: insulin and oral agent treatment
ypertension Indicate if the patient has hypertension as documented by:
● History of hypertension diagnosed and treated with medication, diet, and/or exercise
● Blood pressure greater than 140 mm Hg systolic or 90 mm Hg diastolic on at least 2 occasions
● Blood pressure greater than 130 mm Hg systolic or 80 mm Hg diastolic on at least 2 occasions for
patients with diabetes or chronic kidney disease (25)
More than one of the above may apply. The year of onset (first diagnosis) may be helpful.
yslipidemia Indicate if the patient has dyslipidemia diagnosed and/or treated by a physician or other provider. Criteria
may include documentation of:
● Total cholesterol greater than 200 mg/dl, or
● Low-density lipoprotein (LDL) greater than or equal to 130 mg/dl, or
● High-density lipoprotein (HDL) less than 35 mg/dl, or
● Use of lipid-lowering therapy
Year of onset (first diagnosis) may be helpful.
istory of thyroid disorder Treatment at any time for hyperthyroidism or currently receiving thyroid supplementation for
hypothyroidism.
Year of onset (first diagnosis) may be helpful.
istory of exposure to cardiotoxic
hemotherapy
History of exposure to cardiotoxic chemotherapy:
● Anthracyclines: adriamycin, daunorubicin, doxorubicin, epirubicin, idarubicin, etc.
● Mitoxantrone
● Cyclophosphamide
● Mitomycin C
● Trastuzamab (Herceptin)
Total cumulative dose should be recorded for chemotherapeutic agents.
istory of thoracic radiation History of thoracic radiation therapy.
Specify if radiation therapy was received before/after 20 years of age. Specify location (mediastinal, chest,
breast, or other). Total radiation exposure should be recorded.
istory of exposure to cardiotoxic
ubstances
History of exposure to cardiotoxic substances through substance abuse:
● Cocaine
● Amphetamine
● Ephedrine
● Other (specify)
amily history of sudden cardiac
eath
Family history (parent or sibling) of sudden cardiac death, defined as natural death due to cardiac causes,
heralded by abrupt loss of consciousness. The time and mode of death are unexpected even though pre-
existing heart disease may have been known to be present (26). Sudden death without obvious cause is
considered sudden cardiac death. Traumatic death subsequently proven to be due to sudden loss of
control due to a cardiac problem is included.
Age at time of sudden cardiac death may be specified.
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Data Element Definition
edical History: Heart Failure Risk Factors, continued
amily history of premature
oronary artery disease
Any direct blood relatives (parents, siblings, children) who have had any of the following at age less than
55 years for male relatives or less than 65 years for female relatives (27):
● Angina
● Acute myocardial infarction
● Sudden cardiac death without obvious cause
● Coronary artery bypass graft surgery
● Percutaneous coronary intervention
amily history of muscular
ystrophy
Family history of muscular dystrophy.
amily history of conduction
ystem disease
Family history of early onset of atrial or ventricular arrhythmias or conduction system disease.
amily history of cardiomyopathy Family history of cardiomyopathy (dilated, poorly contracting left ventricle in the absence of coronary
artery disease, arrhythmogenic right ventricular dysplasia (ARVD), hypertrophic heart disease, or other
specific cardiac muscle disease) in one or more first-degree relative
amily history of hypertrophic
ardiomyopathy
Family history of cardiomyopathy, with or without obstruction. May specify etiology if known.
IV status ● HIV seropositive
● AIDS
edical History: Cardiovascular
istory of heart failure Physician documentation or report of any of the following symptoms of heart failure prior to this care
encounter described as unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine
position, fluid retention, low cardiac output secondary to cardiac dysfunction; or the description of rales,
jugular venous distension, or pulmonary edema. A previous hospital admission with principal diagnosis of
heart failure is considered evidence of heart failure history.
Date of first onset may be helpful.
istory of angina History of angina may include:
● Stable angina
● Unstable angina
Dates should be sought for the onset of either stable or unstable angina.
istory of myocardial infarction History of myocardial infarction as determined by any of the following:
● Hospital admission for acute myocardial infarction
● EKG report indicating previous (old) or acute myocardial infarction
● Increase in biochemical marker (creatine kinase or troponin) consistent with myocardial infarction.
Note that low elevation in troponin level may be seen in patients with heart failure and should not by
themselves be considered diagnostic of infarction (15)
● Patient reports history of acute myocardial infarction or heart attack.
Total number of myocardial infarctions and year of the first and the most recent episode may be helpful.
revious coronary artery bypass
raft (CABG)
Coronary artery bypass graft surgery prior to the current encounter.
Total number of CABG procedures and year of most recent may be helpful.
revious percutaneous coronary
ntervention (PCI)
PCI of any type (balloon angioplasty, atherectomy, stent, or other) prior to the current encounter.
Total number of PCI procedures and year of most recent may be helpful.
revious pacemaker or ICD
mplantation
Pacemaker or ICD implantation prior to the current encounter.
Device type (pacemaker, ICD, combination), cardiac chamber(s) involved, and year of implantation may be
helpful.
istory of peripheral embolic
vent
History of peripheral embolic event as determined by:
● Hospital admission for peripheral embolic event
● Patient reports history of peripheral embolic event
● Report of diagnostic or therapeutic procedure indicating presence of peripheral embolic event
(for example, embolectomy, angiography; nuclear study; ultrasound study)Year of the first episode and number of events may be helpful.
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Data Element Definition
edical History: Cardiovascular, continued
istory of atrial arrhythmias History of any of the following atrial arrhythmias:
● Atrial fibrillation or atrial flutter. Specify whether paroxysmal or chronic.
● Atrial tachycardia
● Sick sinus syndrome
● Paroxysmal supraventricular tachycardia
Year of the first and the most recent episode may be helpful.
istory of ventricular arrhythmias History of either of the following ventricular arrhythmias:
● Ventricular tachycardia (sustained/nonsustained)
● Ventricular fibrillation
Specify documentation source (e.g., Holter, event recorder, ICD, pacemaker, etc.). Year of the first and
the most recent episode may be helpful.
istory of arrhythmogenic
isease, syndrome, or substrate
History of any of the following arrhythmogenic conditions:
● Right ventricular (RV) dysplasia
● Brugada syndrome
● Wolf-Parkinson-White syndrome
● Sudden unexpected death syndrome (young Asian males)
● Atrial ventricular nodal re-entrant tachycardia (AVNRT)
● RV outflow tract ventricular tachycardia
● Bundle-branch mediated ventricular tachycardia
Year of the first and the most recent episode may be helpful.
istory of cerebrovascular disease History of cerebrovascular disease, documented by any one of the following:
● Cerebrovascular ischemic or hemorrhagic stroke: patient has a history of stroke (i.e., any focal
neurological deficit of abrupt onset caused by a disturbance in blood supply that did not resolve
within 24 hours) confirmed by a standard neurological examination with or without a positive
imaging study, or an event of presumed ischemic origin that did not resolve within 24 hours, but the
imaging showed a new lesion.
● Transient ischemic attack (TIA): patient has a history of any sudden new focal neurological deficit of
presumed ischemic origin as determined by a standard neurological exam that resolved completely
within 24 hours, with a brain image study not revealing a new lesion.
● Noninvasive/invasive carotid test with greater than or equal to 75% occlusion
● Previous carotid artery surgery
● Previous carotid angioplasty
Year of the first and most recent episode may be helpful.
evel of disability following
troke
Level of disability following stroke:
● Recovered
● Minor persisting disability
● Major persisting disability
istory of peripheral arterial
isease
History of peripheral arterial disease may include:
● Claudication either with exertion or at rest
● Amputation for arterial vascular insufficiency
● Vascular reconstruction, bypass surgery, or percutaneous intervention to the extremities
● Documented aortic aneurysm
Year of the first episode and number of events may be helpful.
istory of rheumatic valvular
isease
History of primary valvular disease may include:
● History of acute rheumatic fever/carditis (usually determined through correspondence with major and
minor criteria [28])
● History of valve disease with echocardiographic findings suggestive of or diagnostic of rheumatic
valvular disease
Year of the first episode may be helpful.
istory of other valvular disease
tiology
History of valvular disease of other etiology (specify):
● Congenital (present at birth or occurring association with congenital heart disease syndrome)
● Degenerative (acquired during adulthood, usually after age 50)
● Infectious (acquired as a result of infectious endocarditis)
● Toxic (for example, as a result of exposure to fenfluramine phentermine dexfenfluramine)
● Other (specify)Year of the first episode may be helpful.
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Data Element Definition
edical History: Cardiovascular, continued
istory of congenital cardiac
esions
History of congenital cardiac lesions including:
● Patent ductus arteriosus
● Atrial septic defect (ASD)
● Ventricular septal defect (VSD)
● Tetralogy of Fallot
● Transposition of great vessels
● Congenitally corrected transposition
● Single ventricle
● Other
Specify type of lesion. Note if lesion has had corrective therapy and specify date of correction.
istory of Chagas disease Documented history of Chagas disease.
edical History: Non-Cardiovascular
istory of asthma History of asthma. For patients with onset of asthma in adulthood, asthma diagnosis should precede
heart failure diagnosis by at least 5 years or have documented pulmonary function test (PFT) evidence of
reversible bronchospasm.
Note: because patients with heart failure may present with wheezing and other clinical features mimicking
asthma, care in distinguishing these conditions from one another is crucial.
istory of chronic renal
nsufficiency
History of reduced glomerular filtration rate for at least 3 months. Degree of renal insufficiency may be
further defined according to degree of depression in glomerular filtration rate (GFR):
● Mild renal insufficiency: GFR 60–89 ml/min/1.73 m2
● Moderate renal insufficiency: GFR 30–59 ml/min/1.73 m2
● Severe renal insufficiency: GFR 15–29 ml/min/1.73 m2
● Renal failure: GFR less than 15 ml/min/1.73 m2, or patient requires chronic dialysis treatment
Note: GFR may be estimated using the serum creatinine–GFR  186  (PCr)
1.154  (age)0.203 
(0.742 if female)  (1.210 if black)
Year of onset (first diagnosis) may be helpful.
istory of acute renal
nsufficiency
History of reduced renal function (see “History of chronic renal insufficiency” element) for less than 3 months.
Year of occurrence of and precipitant for acute renal insufficiency may be specified.
istory of dialysis History of renal dialysis, either by:
● Hemodialysis
● Peritoneal dialysis
Year of onset may be helpful.
istory of chronic lung disease History of chronic lung disease (e.g., chronic obstructive pulmonary disease, chronic bronchitis,
emphysema) or currently being chronically treated with inhaled or oral pharmacological therapy
(e.g., beta-adrenergic agonist, anti-inflammatory agent, leukotriene receptor antagonist, or steroid).
Year of onset (first diagnosis) may be helpful.
istory of dementia History of dementia, Alzheimer’s disease, chronic confusion (at least one month in duration), or senility.
Year of onset (first diagnosis) may be helpful.
istory of depression History of treated depression, or currently taking antidepressant medication. Note if past or present
episode has or is currently requiring drug treatment or electroconvulsive therapy (ECT).
Year of onset (first diagnosis) may be helpful.
istory of liver disease History of chronic hepatitis or cirrhosis.
istory of lupus or collagen
ascular disease
History of collagen vascular disease such as lupus erythematosis, scleroderma, rheumatoid arthritis.
istory of musculo-skeletal
isease
History of primary musculo-skeletal disease, including muscular dystrophy, myasthenia gravis,
dermatomyositis.
istory of malignancy History of cancer, excluding non-melanoma skin cancers.
Cancer site and date of first diagnosis may be helpful.
istory of influenza
mmunization
History of influenza immunization.
Month and year of most recent immunization should be noted.
istory of pneumococcal
mmunization
History of pneumococcal immunization.
Month and year of most recent immunization should be noted.
istory of urinary continence History of urinary continence. Choose from the following categories:
● Continent
● Occasionally incontinent
● Totally incontinent
● Dialysis
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or patients with HF, assessment of signs and symptoms is
irected toward evaluation of volume status and cardiac
utput. For all symptoms reported by the patient, consider
ollecting time-frame (onset, current, course, and so on) and
hange in symptoms since last visit (better, worse,
able 3. Patient Assessment: Current Symptoms and Signs
Data Element
linical Symptoms
yspnea at rest Patient describes frequent unco
Date of onset and duration ma
yspnea on exertion Patient describes uncomfortabl
Indicate degree of activity requ
● Running or other sport (sp
● Walking up an incline (spe
● Walking on a flat surface (
● Stopping to rest while dres
● Standing (specify length of
● Other activity (i.e., shoppin
Date of onset and duration ma
rthopnea Patient describes at least one o
● Uncomfortable awareness o
● Positioning with 3 or more
sleep
● Recurrent supine cough wi
Date of onset and duration ma
aroxysmal nocturnal
yspnea
Patient describes awakening su
distress relieved by the upright
considered positive.
Date of onset and duration ma
eight gain or loss Amount of weight gain or loss
Time frame over which weight
welling Patient reports swelling or puffi
Date of onset and duration ma
atigue Patient describes unusual tiredn
Date of onset and duration ma
ngina Angina refers to previous or cu
other equivalent discomfort sug
classification (29) is useful in d
● Grade I: ordinary physical
occurs with strenuous or ra
● Grade II: slight limitation
after meals, in cold, in winnchanged). For inpatient care encounters, the first patient
ssessment (history and physical examination) should be
eported.
Often these data can be captured with health status
nstruments. Please see Appendix A for discussion of
ystematic collection of patient’s functional status using
tructured survey/questionnaire instruments.
Definition
able awareness of breathing while resting in a sitting position.
elpful.
reness of breathing while exerting him/herself.
o elicit dyspnea symptom:
sport)
istance)
y distance)
housework; specify)
elpful.
following:
thing while in a supine position
ws or in a chair or recliner to maintain comfortable breathing during
other known cause may be an orthopnea equivalent
elpful.
y from sleep with uncomfortable awareness of breathing, or with general
ion. Any report of this symptom lasting greater than 5 minutes is
elpful.
ounds or kilograms, as reported by the patient.
ge occurred should be noted.
in extremities, abdomen, and/or other areas.
elpful.
nd inability to perform usual activities.
elpful.
symptoms described as chest pain or pressure, jaw pain, arm pain, or
e of cardiac ischemia. The Canadian Cardiovascular Society angina
ining the level of angina:
y does not cause angina—for example walking or climbing stairs, angina
r prolonged exertion at work or recreation.
inary activity—for example, angina occurs walking or stair climbing
er emotional stress or only during the few hours after awakening,mfort
y be h
e awa
ired t
ecify
cify d
specif
sing
time)
g or
y be h
f the
f brea
pillo
thout
y be h
ddenl
posit
y be h
, in p
chan
ness
y be h
ess a
y be h
rrent
gestiv
eterm
activit
pid o
of ord
d, und
walking more than two blocks on the level or climbing more than one flight of ordinary stairs at a
normal pace and in normal conditions.
● Grade III: marked limitation of ordinary activity—for example, angina occurs walking one or two blocks
on the level or climbing one flight of stairs in normal conditions and at a normal pace.
● Grade IV: inability to carry on any physical activity without discomfort—angina syndrome may be
present at rest.
Year of onset (first diagnosis) may be helpful.
yncope Sudden loss of consciousness not related to anesthesia, with spontaneous recovery as reported by patient or
observer. Patients losing consciousness prior to an implantable cardiac defibrillator (ICD) discharge will be
considered to have syncope.
Date of most recent episode may be helpful.
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pecific HF etiologies are provided for those data collection
fforts that require a more specific delineation than “ischemic
r non-ischemic.” The possible etiologies allow for a pick-and-
hoose approach. A primary etiology and/or multiple etiologies
ay be chosen. The definitions of HF etiologies have been
onstructed to imply causality and not merely association. The
ist of potential etiologies represents a compromise between
able 3 Continued
Data Element
hysical Examination
eart rate Heart rate (beats per minute) r
on discharge (for inpatient). Sp
Heart rate may be ascertained
ystolic and diastolic blood
ressure
Systolic and diastolic blood pre
facility. Patient position (supin
ugular venous pressure The estimated height of the m
as cm without further descripti
above the sternal angle, 5 cm s
estimate of jugular venous pres
to the jaw” or “to the angle of
espiratory rate Respiratory rate in respiratory c
eight Patient’s height in centimeters
eight at encounter Patient’s weight in kilograms o
clothing worn (i.e., whether sh
ody mass index (BMI) Calculated according to formul
is defined as BMI greater than
hird heart sound (S3) Presence or absence of a third
ourth heart sound (S4) Presence or absence of a fourth
eart murmur Presence or absence of heart m
and intensity of each murmur s
Intensity is usually graded on 1
ung (pulmonary)
xamination
Lung (pulmonary) findings by
● Clear or normal
● Rales (height of rales when
● Decreased breath sounds or
● Rhonchi
● Wheezing
Other findings (for example, pl
eripheral edema Increased tissue fluid indicated
scites Intra-abdominal fluid accumula
epatomegaly Documentation of liver edge d
hepatomegaly is present if liver
epatojugular reflux (HJR) Presence or absence of hepatoju
obility Assessment of patient’s mobilit
● Able to walk independently
● Able to walk with assistanc
● Unable to walk; mobility re
● Bedriddenrevity and comprehensiveness.Although the New York Heart Association (NYHA)
unctional class (30) has proven useful as a measure
ummarizing the patient’s overall HF symptom burden, it
ay be imprecise, subject to substantial interobserver
ariability, and may change over time. Heart failure stage
18) and patient-reported health status (21,31,32) are
merging as important constructs for delivering and
valuating HF care.
Definition
ed closest to the time of presentation to the health care facility and/or
whether heart rate is regular or irregular.
electrocardiographic tracing or from record of physical examination.
(mm Hg) recorded closest to the time of presentation to the health care
ing, other) may be noted.
gular venous waveform above the right atrium in cm. When expressed
e number should be recorded as written. When it is expressed as cm
be added to the number recorded. In the absence of a numerical
“jugular venous distension (JVD),” “distended neck veins,” and “halfway
w” would be recorded as positive for elevated jugular venous pressure.
per minute.
hes. May be measured or reported by patient.
nds. Must be measured during encounter. It is advisable to standardize
e worn).
ient’s weight in kilograms, divided by height in meters squared. Obesity
ual to 30 kilograms per meter squared.
diastolic) heart sound.
-diastolic) heart sound.
r(s). Timing (systolic, diastolic), quality (harsh, blowing, ejection, etc.),
be noted.
ale for systolic murmurs and 1–4 scale for diastolic murmurs.
ltation:
nt sitting upright should be noted)
ess
rub) may also be noted.
rceptible indentation on lower leg or foot after palpation.
as determined by physical examination.
ble below the right costal margin during physical examination. Marked
is detected 8 cm or more below the right costal margin.
reflux (HJR). Degree of HJR should be noted.
e, walker, etc.)
s assistance (wheelchair, etc.)ecord
ecify
from
ssure
e, sitt
ean ju
on, th
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Data Element Definition
eart Failure Etiology
vidence for ischemic heart
isease
Any of the following conditions indicates ischemic heart disease:
● At least one major epicardial coronary artery with more than 70% obstruction by coronary angiography
● History of acute myocardial infarction associated with wall motion abnormality by echocardiography or gated
blood pool imaging
● Stress testing (with or without imaging) diagnostic of coronary artery disease
vidence for valvular heart
isease
Primary valvular disease:
● Moderately severe or severe, or 3 or 4 aortic insufficiency
● Moderately severe or severe, or 3 or 4 mitral insufficiency with echocardiographic evidence that mitral
insufficiency is a primary abnormality, and not secondary to ventricular dilation
● Moderately severe or severe aortic stenosis defined by estimated aortic valve area by catheterization or
Doppler echocardiography of less than or equal to 1.0 cm2
● Moderately severe or severe mitral stenosis defined by estimated mitral valve area by catheterization or
echocardiography of less than 1.0 cm2
Contributory valvular disease:
● Valve disease that is felt to be significant but does not fulfill the above definitions
vidence for myocardial
nfiltrative or storage disease
● Systemic amyloidosis by biopsy
● Hemochromatosis by biopsy or by serum markers in the presence of clinical evidence of multi-organ involvement
● Heart failure in a patient with a storage disease known to involve the myocardium, including Fabry disease,
Gaucher disease, or the glycogen storage diseases
vidence for inflammatory
yocarditis
● Biopsy-proven myocarditis
● Sarcoidosis with biopsy evidence or diagnostic pulmonary radiographic appearance with reduced left ventricular
systolic function
● Documented Chagas disease
vidence for primary
yocardial hypertrophic
uscle disease
Any of the following conditions indicates evidence for primary myocardial hypertrophic muscle disease:
● Evidence for symmetric or asymmetric hypertrophy with or without outflow tract obstruction
● Congenital muscular dystrophy
vidence for hypertensive
ardiomyopathy
One of the following conditions must be met:
● Untreated systolic blood pressure greater than 160 mm Hg or diastolic greater than 105 mm Hg for at least
3 months
● Hypertension requiring at least 2 drugs for control for at least 5 years
● Presence of diabetes and hypertension, treated or untreated
● Documented left ventricular hypertrophy (preferably by echocardiography or MRI)
● Absence of other etiologies for heart failure
vidence for toxic
ardiomyopathy
● Alcohol abuse present for at least 5 years as defined by either heavy alcohol consumption (i.e., 75 g/day at least
5 days/wk) or alcohol dependence
● Cocaine use
● Ephedrine use
● Temporally-related exposure to a drug or substance known to cause cardiomyopathy, including chemotherapeutic
agents(s) and radiation to the chest
vidence for pregnancy-
elated cardiomyopathy
Onset of cardiomyopathy associated with pregnancy (peri-, post-partum).
Indicate whether cardiomyopathy appears to be:
● Reversed/resolved, or
● Irreversible, causing permanent damage to the myocardium
vidence for thyroid disorder-
elated cardiomyopathy
Presence of otherwise unexplained cardiomyopathy associated with thyroid disorder.
vidence for arrhythmogenic
ight ventricular dysplasia
ARVD) cardiomyopathy
Arrhythmogenic right ventricular dysplasia (AVRD) is characterized by progressive fibrofatty replacement of right
ventricular myocardium and right ventricular dysfunction, regional or global, usually demonstrated by
echocardiography or cardiac magnetic resonance imaging. It is associated with arrhythmias and sudden death (33).
vidence for idiopathic
ardiomyopathy
Heart failure and reduced systolic function without evidence for any of the above etiologies or other disease known
to cause cardiomyopathy.
amilial cardiomyopathy ● Possible familial cardiomyopathy: presence of otherwise unexplained cardiomegaly, diagnosis of heart failure, atrial
fibrillation or life-threatening ventricular arrhythmias, conduction system disease, or sudden death in first degree
relative under 60 years of age
● Probable familial cardiomyopathy: presence of above in two relatives under 60 years of age who are related to
each other and the patient
EW
m
o
l
m
s
h
a
s
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
F
D
p
T
H
E
d
t
E
d
H
N
(
H
(
iscus
1194 Radford et al. JACC Vol. 46, No. 6, 2005
Chronic Heart Failure in the Adult: ACC/AHA Clinical Data Standards September 20, 2005:1179–207. Laboratory Tests
hen collecting information about laboratory tests, the
inimum suggested data to capture are: 1) value, 2) unit
f measurement, 3) date, and 4) normal range (upper
imit of normal when appropriate). More detailed infor-
ation can be collected as needed. For outpatient care,
erial values should be recorded, with dates to reflect first,
ighest, and lowest values. For inpatient care assessment,
t least the first value obtained closest to admission
hould be recorded.
Sodium
Potassium (first, highest, and lowest values)
Calcium
Magnesium
TSH (thyroid-stimulating hormone)
able 4 Continued
Data Element
eart Failure Etiology, continued
vidence for ventricular
ysfunction due to
achyarrhythmias
Heart failure attributed to sustained (u
min) that is not attributable to any ot
vidence for ventricular
ysynchrony
Ventricular dysynchrony evidenced by
(IVCD), bundle branch block (BBB).
eart failure stage (17) ● A  patient at high risk for develop
● B  patient with a structural disord
● C  patient with past or current sym
● D  patient with end-stage disease
support, continuous inotropic infusio
ew York Heart Association
NYHA) class (30)
NYHA class as reported by a physicia
● Class I: patients with cardiac disea
activity does not cause undue fatig
● Class II: patients with cardiac dise
rest. Ordinary physical activity res
● Class III: patients with cardiac dis
at rest. Less than ordinary activity
● Class IV: patients with cardiac dis
Symptoms are present even at rest
ealth status
see Appendix A)
Health status of patient at the time of
● 5-Point Likert Scale
● Visual Analog Scale Score
● Minnesota Living with Heart Fail
● Kansas City Cardiomyopathy Que
● SF-36 or SF-12
● Other
See Appendix A for a more detailed dCBC (complete blood count) sBlood urea nitrogen (first and highest values)
Serum creatinine (first and highest values)
Hemoglobin A1C
Hemoglobin or hematocrit (specify which)
Serum albumin
Glucose (fasting)
Total cholesterol
HDL (high-density lipoprotein) cholesterol
LDL (low-density lipoprotein) cholesterol
Triglycerides
INR (international normalized ratio)
BNP (brain natriuretic peptide) or N-terminal BNP
. Diagnostic Procedures (Table 5)
iagnostic procedures may be noted as either having been
erformed or the findings described. Date of procedure
Definition
y greater than 1 week) tachycardia (usually greater than 120 beats per
use and shows evidence for improvement after correction.
greater than or equal to 120 ms, intraventricular conduction delay
eart failure but who has no structural disorder of the heart
the heart but who has never developed symptoms of heart failure
s of heart failure associated with structural heart disease
equires specialized treatment strategies such as mechanical circulatory
rdiac transplantation or hospice care
t without resulting limitations of physical activity. Ordinary physical
alpitation, or dyspnea.
sulting in slight limitation of physical activity. They are comfortable at
fatigue, palpitation, or dyspnea.
resulting in marked limitation of physical activity. They are comfortable
s fatigue, palpitation, or dyspnea.
esulting in inability to carry on any physical activity without discomfort.
inimal exertion.
as documented by one of the following:
uestionnaire
naire
sion of potential measures.suall
her ca
QRS
ing h
er of
ptom
who r
ns, ca
n:
se bu
ue, p
ase re
ults in
ease
cause
ease r
or m
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ure Q
stionhould be recorded.
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Data Element Definition
jection fraction (EF) Quantitative measurement of ejection fraction is preferred over qualitative measurement.
● Quantitative:
- Ejection fraction, measured in percent
- When a quantitative range is given, the midpoint of the range
● Qualitative:
- Normal (corresponds to LVEF greater than 50%)
- Mildly diminished (corresponds to LVEF 41% to 49%)
- Moderately diminished (corresponds to LVEF 26% to 40%)
- Severely diminished (corresponds to LVEF 25% or less)
When multiple determinations are present, the hierarchy should be:
● Radionuclide ventriculography
● Magnetic resonance imaging (MRI)
● Echocardiography
- 2-dimensional
- 3-dimensional
● Contrast ventriculography
● Technetium myocardial perfusion imaging
● Other
jection fraction modality Modality used to determine the ejection fraction:
● Radionuclide ventriculography
● Magnetic resonance imaging (MRI)
● Echocardiography
- 2-dimensional
- 3-dimensional
● Contrast left ventriculography
● Technetium myocardial perfusion imaging
● Other
When multiple measures are available, the most recent is preferred.
adionuclide
entriculography
Cardiac blood pool imaging (first pass or gated equilibrium) with or without stress.
Documented findings may include:
● LVEF: percentage (range 5% to 90%) for left ventricle
● RVEF: percentage (range 5% to 90%) for right ventricle
chocardiography Resting two-dimensional or three-dimensional echocardiography with or without Doppler imaging.
Ejection fraction or description of left ventricular systolic function should be enumerated as above.
Other findings may include:
● Description of right ventricular size and function
● Description of focal left ventricular wall motion abnormalities
● Valvular regurgitation (mitral, aortic, tricuspid, pulmonic), by Doppler color flow mapping:
- Qualitative descriptors: none or trace, mild, moderate, moderate-severe, severe, not evaluated
- Quantitative descriptors: none or trace, mild, moderate, moderate-severe, severe, not evaluated
● Valvular stenosis (aortic, mitral), by continuous wave and/or pulsed wave Doppler interrogation. Maximum
velocities, peak gradient, mean gradient, and/or valve area may be determined and reported using standard
techniques.
● Presence or absence of pericardial echo-free space, with description of whether there is imaging and/or
Doppler evidence for hemodynamic significance
● Maximum tricuspid regurgitant velocity, when present, to estimate pulmonary artery systolic pressure
● Presence or absence of evidence for left ventricular diastolic dysfunction (ratio of early to atrial transmitral
filling velocity by Doppler; description of pulmonary venous Doppler inflow pattern; deceleration time, and
so on)
● Presence or absence of patent foramen ovale (PFO)
● Left ventricular end-diastolic dimension (mm). M-mode, parasternal view.
● Left ventricular end-systolic dimension (mm). M-mode, parasternal view.
● Left ventricular wall thickness (mm). M-mode, parasternal view, both septum and posterior wall.
● Left atrial dimension (mm). M-mode, parasternal view, inferior vena cava (IVC) diameter.
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Data Element Definition
lectrocardiography 12-lead electrocardiography. Documented findings may include:
● Rhythm:
- Sinus rhythm
- Atrial fibrillation or flutter
- Paced or other rhythm
● Heart rate (beats per minute)
● Left bundle branch block (LBBB), Minnesota criteria (34)
● Right bundle branch block (RBBB), Minnesota criteria (34)
● Location of abnormal Q waves (0.03 second in width and 1 mm [0.1 mV] in depth in at least
2 contiguous leads)
● QRS duration (in milliseconds): may be reported as the measured duration, or categorically as shorter than
120 milliseconds; 121 to 150 milliseconds; or longer than 150 milliseconds
● Heart block:
- None
- 1st degree
- 2nd type 1 (Wenckebach)
- 2nd type 2
- 3rd degree
hest radiography Radiological examination of the chest. Documented findings from the chest X-ray pertinent to heart failure
patients may include:
● Pulmonary vascular redistribution, pulmonary congestion, or pulmonary edema
● Cardiomegaly
● Pleural effusion(s)
yocardial perfusion imaging Radionuclide myocardial perfusion imaging (planar or SPECT) with or without stress (PET listed separately).
Documented findings may include:
● Stress-induced perfusion abnormalities
● Fixed perfusion abnormalities
● Perfusion imaging LVEF: percentage 5% to 90% for LV from perfusion (technetium) imaging
● Regional wall motion assessment
oronary angiography Coronary angiography with or without left heart catheterization. Documented findings may include stenosis of
any epicardial coronary artery (right, left anterior descending, circumflex) or major branch (diagonal, marginal).
Degree (percentage) of stenosis should be specified. Coronary arteries may have insignificant or no stenosis.
Bypass graft angiography may also be performed and reported.
eft heart catheterization Left heart catheterization with or without coronary angiography or ventriculography. Documented findings may
include:
● Left ventricular end diastolic pressure (mm Hg). Pressure from left ventricular catheter at end-diastole.
● Left ventriculography ejection fraction. Percentage 5% to 90% from left ventricular injection.
ight heart catheterization Right heart catheterization with or without pulmonary angiography. Documented findings may include:
● RA pressure (mm Hg): mean right atrial pressure from pulmonary artery catheter
● PA systolic pressure (mm Hg): systolic pulmonary pressure from pulmonary artery catheter
● PA diastolic pressure (mm Hg): diastolic pulmonary pressure from pulmonary artery catheter
● Mean pulmonary artery occlusion pressure from pulmonary artery catheter (wedge pressure, mm Hg). May
be recorded with or without V-wave.
● Cardiac output/index (liters or milliliters per minute, specify which)
● Pulmonary vascular resistance (Wood’s units, or dynes/second/cm)
● Systemic vascular resistance (dynes/second/cm2)
agnetic resonance imaging
MRI)
Magnetic resonance imaging (may include angiography) of the chest. Document ejection fraction percentage if
measured as part of the MRI.
● Ejection fraction: document ejection fraction percentage if measured as part of the MRI
● Ventricular volume assessment
● Regional wall motion assessment
omputerized axial
omography (CT scan)
Computerized axial tomography of the chest.
● Ejection fraction: document ejection fraction percentage if measured as part of the CT scan
● Ventricular volume assessment
● Regional wall motion assessment
eart biopsy Biopsy of the endomyocardium.
ositron emission
omography (PET)
Positron emission tomography of the myocardium including perfusion imaging and stress studies. Documented
findings may include:
● PET metabolic deficits
● PET baseline perfusion deficits
● PET metabolic/perfusion mismatch
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any cardiovascular diseases that either play a role in
ausing HF or influence its course are treated with invasive
herapeutic procedures. A uniform description of the type of
rocedure and its indication for use would enhance coher-
able 5 Continued
Data Element
tress testing Cardiovascular stress test includin
findings may include:
● Maximal (symptom limited) o
● Workload achieved. May be e
metabolic equivalents (METS
● Reason for terminating exercis
- Chest pain
- Dyspnea
- Dizziness
- Leg fatigue
- Other discomfort (specify)
- Tachyarrhythmias
- Asymptomatic tachyarrhyth
● Evidence for ischemia on stres
- Positive: on an exercise tole
● Greater than or equal to
at least 60 to 80 milliseco
● New ST-segment depress
believed to represent ische
equivalent type of exercise
dipyridamole, thallium, or
an area of clear reversible
- Negative: no evidence of is
evidence for ischemia)
-minute walk test Distanced walked during 6-minut
ontinuous ambulatory ECG
onitoring for heart failure
Specify type of ambulatory ECG
monitor, Holter monitor).
Significant findings may include:
● Duration of monitoring
● Mean heart rate, as well as mi
● Number and/or density of ven
● Number of episodes of non-su
beats per min)
● Number of episodes of sustain
100 beats per min)
● Number of pauses greater than
● Heart rate variability (normal/
● Presence of persistent or episoValve(s) and procedure(s) may be specifiednce between clinical and research databases used to follow
atients with HF. The procedures listed in this section are
mong those frequently applied to patients who may have
ither impaired cardiac function or clinical HF. Date and
ndication should be specified for all procedures.
Definition
cise (treadmill, bicycle) and pharmacological stress. Documented
aximal test
ed as Watts, exercise stage achieved (include exercise protocol) or
:
(positive or negative):
test, the patient developed either:
of horizontal or downsloping ST-segment depression or elevation for
ms) after the end of the QRS complex, in asymptomatic patients, or
reater than or equal to 2 mm (0.2 mV) (horizontal or downsloping)
ven in the absence of ischemic discomfort. If the patient had an
(e.g., exercise thallium or MIBI test, stress echocardiography, or
osine radioisotope scan) that showed definite evidence of ischemia (e.g.,
mia), this should be considered a positive test.
a (i.e., no typical angina pain and no ST depressions, no imaging
(on a flat surface), in feet or meters.
or used (e.g., looping event monitor, implantable looping event
m and maximum for patients in atrial fibrillation
ar extrasystoles
d ventricular tachycardia (3–15 consecutive beats at greater than 100
ntricular tachycardia (greater than or equal to 30 seconds at greater than
seconds
mal/not assessed)
rial fibrillation, including duration and number of episodesable 6. Invasive Therapeutic Procedures
Data Element Definition
urgical Procedures
oronary artery bypass graft
CABG) surgery
The number and types of grafts and surgical approach may be further specified:
● Number and placement of vein bypass grafts
● Number and placement of arterial bypass grafts
● Standard bypass surgery approach
Approach may be further specified:
● Median sternotomy approach
● Small thoracotomy
● With or without cardiopulmonary bypass
ransmyocardial laser
evascularization (TMLR)
Transmyocardial laser revascularization (TMLR) performed either alone or in combination with CABG.
alve repair Mitral, aortic, and/or tricuspid valve surgical repair. Use of valve ring may be specified.g exer
r subm
xpress
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e test
mias
s test
rance
1 mm
nds (
ion g
mia e
test
aden
ische
chemi
e walk
monit
nimu
tricul
staine
ed ve
2.4
abnor.
TS
V
V
V
s
S
h
P
P
C
o
d
S
d
A
I
s
O
E
P
i
I
d
1198 Radford et al. JACC Vol. 46, No. 6, 2005
Chronic Heart Failure in the Adult: ACC/AHA Clinical Data Standards September 20, 2005:1179–207able 6 Continued
Data Element Definition
urgical Procedures, continued
alve replacement Mitral, aortic, tricuspid, and/or pulmonic valve surgical replacement with prosthetic valve. Valve prosthesis should
be specified.
Valve(s) and procedure(s) may be specified.
alvuloplasty Valvuloplasty for stenotic valve lesions (aortic, mitral, pulmonic).
Valve(s) and procedure(s) may be specified.
entricular remodeling
urgery
Ventricular remodeling surgery may include:
● Aneurysectomy
● Anterior ventricular resection (surgical anterior ventricular restoration [SAVR], Dor procedure)
urgical intervention for
ypertrophic cardiomyopathy
Hypertrophic cardiomyopathy may be treated by:
● Septal myectomy
● Septal myectomy with mitral valve replacement or repair
ericardiectomy Surgical removal of the pericardium, usually because of constrictive pericardial disease or infection.
ericardiocentesis, surgical Surgical drainage of fluid in the pericardium.
losure of patent foramen
vale (PFO) or atrial septal
efect
Open surgical PFO closure or correction of atrial septal defect may be performed for:
● Stroke
● Left to right shunt
● Right to left shunt
urgery for congenital heart
isease
● Fontan procedure
● Mustard procedure
● Senning procedure
● Other procedure
trial fibrillation surgery Maze or modified Maze procedure.
mplantable circulatory
upport
May be pulsatile or non-pulsatile flow devices. Implantable circulatory support includes:
● Left ventricular assist device (LVAD)
● Right ventricular assist device (RVAD)
● Biventricular assist device (BiVAD)
● Artificial heart
rgan transplantation Organ transplantation may encompass:
● Heart
● Heart/lung
● Lung, single/double
● Kidney
● Liver
● Other (may include combination of organs)
lectrophysiological Procedures
ermanent pacemaker
mplantation
Permanent pacemaker implanted, usually transvenous. Specify pacemaker placement:
● Dual chamber (DDD)
● Right ventricular (VVI)
● Right atrial (AAI)
● Anti-tachycardia
● Biventricular pacing for heart failure
● Left ventricular pacing for heart failure
The brand, model number, and serial number may be recorded.
mplantable cardioverter-
efibrillator (ICD)
Implantable cardioverter-defibrillator may be placed for:
● Ventricular fibrillation (VF)
● Symptomatic ventricular tachycardia (VT)
● Asymptomatic ventricular tachycardia (VT)
● Other (specify)
● Inducible VT/VF at EP study
● Syncope
● Primary prevention for patients in high risk heart failure groupThe brand, model number, and serial number may be recorded.
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or each pharmacological therapy element, administration
r prescription of a medication in the specified class should
e noted. In addition, particularly for clinical care, consider
ecording specific medication, total daily dose, start date,
nd stop date (when applicable). For combination therapies
e.g., combination diuretic and ACE inhibitor), both classes
f medications should be indicated. Accurate and complete
able 6 Continued
Data Element
ercutaneous Interventional Procedures
ercutaneous coronary
ntervention (PCI)
Percutaneous coronary intervention (
● Percutaneous transluminal corona
● Stent placement (may be drug-el
● Directional atherectomy
● Rotational atherectomy
● Intracoronary brachytherapy
lectrophysiologic (EP)
atheter ablation
EP ablation may be performed for:
● Supraventricular tachycardia (SVT
● Atrial fibrillation (AF)
● Atrial flutter
● Ventricular tachycardia (VT)
● Wolf-Parkinson-White (WPW)
● Atrioventricular nodal reentrant t
eripheral vascular
ntervention
Peripheral vascular intervention may
● Percutaneous transluminal angiop
● Stent placement
● Aortic stent graft
● Surgical bypass
● Aneurysectomy
● Carotid stenting
● Carotid endarterectomy
● Other
Specify vessel.
ercutaneous myocardial laser
evascularization (PMLR)
Percutaneous myocardial laser revascu
laser revascularization.
ercutaneous intervention for
ypertrophic cardiomyopathy
Hypertrophic cardiomyopathy may b
● Ethanol septal ablation
ercutaneous
ericardiocentesis
Percutaneous drainage of fluid in the
ther percutaneous procedures Other percutaneous procedures inclu
● Valve replacement
● Valve repair
● Valvuloplasty
● Closure of patent foramen ovale
● Closure of secundum atrial septa
● Closure of patent ducus arteriosu
Specify type of date of procedure, typ
irculatory/Ventilatory Support
xtra-corporeal circulatory
upport
Extra-corporeal circulatory support in
● Intra-aortic balloon counterpulsat
● Extracorporeal membrane oxygen
echanical ventilatory
upport
Mechanical ventilatory support includ
● Mechanical ventilation/intubation
● CPAP
● BiPAP
Specify dates of initiation and terminnformation about pharmacological therapy can be facili- pated by appending a list of drugs in each class that are
ommonly available for the setting and population under
valuation.
For all medications recommended with Class I evidence
upporting the ACC/AHA Clinical Performance Measures
or Heart Failure (19), it is prudent to collect all potential
ontraindications. As of now, those medications include ACE
nhibitors, beta-blockers, and warfarin anticoagulation (for
Definition
may include:
gioplasty (PTCA)
stent)
ome
ardia (AVNRT)
e:
tion performed either alone or in conjunction with transmyocardial
utaneously treated by:
ardium.
ct (ASD)
A)
device, and congenital defect.
s:
IABP)
(ECMO)
of therapy.PCI)
ry an
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)
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Data Element Definition
herapies for HF
ldosterone inhibitor Patient has been prescribed an aldosterone inhibitor.
ngiotensin-converting enzyme (ACE)
nhibitor medication
Patient has been prescribed an angiotensin-converting enzyme (ACE) inhibitor.
ngiotensin II receptor blocker (ARB)
edication
Patient has been prescribed an angiotensin receptor antagonist blocker (ARB) medication.
eta-adrenergic antagonist (beta-blocker)
edication
Patient has been prescribed a beta-adrenergic antagonist (beta-blocker) medication.
igitalis Patient has been prescribed digitalis.
iuretic medication Patient has been prescribed a diuretic. Aldosterone inhibitor is listed separately above.
lectrolytes Patient has been prescribed electrolytes:
● Potassium
● Magnesium
xperimental drugs/clinical trial drugs Patient participating in investigational new drug trial.
List drug class being tested. Record date patient enrolled in trial.
ntravenous (IV) inotropic agent Intravenous positive inotrope administered.
ntravenous (IV) natriuretic peptide Intravenous natriuretic peptide administered.
ntravenous (IV) vasodilator agents Intravenous vasodilator administered.
orphine sulfate Morphine sulfate may be administered orally or intravenously. May be administered for pain or
pulmonary edema.
itrate therapy Nitroglycerin may be topical, oral, or sublingual.
Nitroglycerin used on an as-needed basis only should be noted in this category.
ral vasodilators Patient has been prescribed an oral vasodilator, other than specified in any above classes. Oral
vasodilators most commonly prescribed for heart failure are nitrates (see “Nitrate therapy”) and
hydralazine. Other oral vasodilators may be prescribed to treat hypertension.
xygen therapy Patient has been prescribed oxygen for chronic use.
ntiarrhythmic agent Antiarrhythmic drug administered. As antiarrhythmics other than amiodarone are generally
contraindicated in patients with heart failure, specific indications for their use should be noted.
alcium channel blockers Calcium channel blockers administered. As calcium channel blockers are generally
contraindicated in patients with heart failure, specific indications for their use should be noted.
ipid-lowering agent Lipid-lowering agent administered. Note the type of agent: statin (HMG Co-A reductase
inhibitors), fibrates, nicotinic acid, resin drugs, other.
spirin Patient has been prescribed aspirin.
on-aspirin anti-platelet agent Patient has been prescribed a non-aspirin anti-platelet agent.
arfarin Patient has been prescribed warfarin. Target INR may also be helpful to collect.
eparin Patient has been prescribed heparin. Type of heparin may be specified.
ntidepressants Patient has been prescribed an antidepressant.
emale hormone replacement therapy Patient has been prescribed female hormone replacement therapy.
nfluenza immunization Patient has been immunized for influenza.
nhaled bronchodilator Patient has been prescribed an inhaled bronchodilator.
nsulin Patient has been prescribed insulin.
on-steroidal anti-inflammatory drug (NSAID) Patient has been prescribed a non-steroidal anti-inflammatory drug. As NSAIDs are generally
contraindicated in patients with heart failure, specific indications for their use should be noted.
ral hypoglycemic agent Patient has been prescribed an oral hypoglycemic agent for treatment of diabetes. Specify
agent.
neumococcal immunization Patient has been immunized for pneumococcal pneumonia.
itamins, food supplements, and other non-
rescription treatments
Therapy should be specified and may include vitamins, food supplements, homeopathic
treatments.
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atients’ preferences for treatment, particularly life-sustaining
reatments, change over time. Providers need to assess patients’
references regularly to help patients and family members
able 7 Continued
Data Element
edication Allergy/Side Effects
edication allergy Patient has allergy
● Medication ca
● Allergic reacti
Date of allergic re
edication side effect Patient experience
● Medication as
● Side effect wh
● Whether or n
Date of side effecake the appropriate choices and decisions. a
o
p
i
a
r
with family support is identified.atients with HF who are near the end of life experience
yspnea and pain, and providers need to work to assure that
ymptoms are adequately managed and that patients remain as
omfortable as possible (35). Patients and family members also
equire assistance from nurses and physicians in dealing with
Definition
edication. The following should be specified:
allergy
n may be specified.
e effect from medication. The following should be specified:
ed with side effect
ccurred
dication was discontinued
or medication discontinuation may be specified.nxiety and loss.. Patient Education:
ssessment of Status (Table 9)
actors that negatively influence learning and self man-
gement, including cognitive impairment, low literacy or
anguage skills, visual disturbances, depression, and lack
able 8. End of Life Management
Data Element
imitation of resuscitation Any documented order or decision
restore circulation or ventilation (e
o not resuscitate (DNR) Explicit documentation by physicia
in the event of circulatory or respir
nactivation of ICD
efibrillation mode
Documentation of inactivation of I
specific surgical procedures).
dvance care planning Documentation of discussion carri
directive.
able 9. Patient Education: Assessment of Status
Data Element
ssessment of Learning Readiness
resence of cognitive impairment Documentation in the medical reco
qualitative statement (for example,
ow literacy skills Documentation in the medical reco
anguage skills Documentation in the medical reco
isual disturbances Documentation in the medical reco
macular degeneration).
earing impairment (uncorrected) Documentation in the medical reco
epression Documentation in the medical reco
demonstrates depressed mood or af
evel of caregiver/family support Documentation in the medical reco
patient in current living situation. Uf family or caregiver support, are common among HF
atients (36–38), and should be assessed prior to educat-
ng patients. Additionally, patients’ understanding of and
dherence to care recommendations should be assessed
egularly.
Definition
rding patient request to limit a component of emergency therapy to
o intubation, no chest compressions).
/or patient indicating that no resuscitative efforts are to be performed
arrest.
defibrillation mode without plans to re-activate (excludes inactivation for
t with the patient and/or family (by physician or nurse) about advance
Definition
at patient is cognitively impaired. Documentation may take the form of a
ntia) or a score on a formal mental status assessment.
at the patient does not read or write well or is unable to read or write.
the patient’s preferred language for communication.
at the patient has impaired sight (e.g., blindness, partial blindness,
at the patient has an uncorrected hearing impairment.
at the patient carries the diagnosis of depression, or that the patient
See section on “Medical History: Non-Cardiovascular”).
the living situation of the patient and level of support available to the
y this is described as good, adequate, or inadequate, or a specific problemrega
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ntervention and Referral (Table 10)
ssential components of an educational program for pa-
ients with HF have been identified by several authors
22,39,40). Patient education may be provided by a physi-
ian or nurse. Other providers may supply specialized
ducation (e.g., pharmacists, dietitians, exercise physiolo-
ists). Patient education is most effective when individual-
able 9. Patient Education: Assessment of Status
Data Element
ssessment of Learning Readiness, continued
edication adherence history History confirming adherence to m
utrition history History confirming adherence to in
ow-sodium diet history History confirming adherence to di
moking cessation history If a current smoker, has the patient
lcohol abstinence history History confirming adherence to al
ctivity level history History confirming adherence to ac
aily weight history History confirming adherence to se
aily blood pressure/heart rate
history
History confirming adherence to seinfluenza and pneumococcal immunizzed, based on patient assessment, and occurs over time
ith reinforcement from providers. Inclusion of family
embers in care may facilitate learning and behavior
hange. Multidisciplinary and transitional care models that
requently provide strong patient educational components
ave been effective in reducing hospitalizations and improv-
ng quality of life among patients with HF (10 –
2,20,23,41,42). Date of intervention may be useful.
Definition
ion regimen in the past.
ions regarding adequate nutrition.
sodium restriction in the past.
rgone smoking cessation counseling in the past?
abstinence, if patient has history of alcohol abuse.
level and exercise program.
nitoring of daily weight.
nitoring of daily blood pressure and heart rate.able 10. Patient Education: Intervention and Referral
Data Element Definition
ducation/Counseling Intervention
edication instruction Verbal and written medication instructions provided to patient and/or family.
ecognition of worsening
ymptoms
Verbal and written instructions provided to patient and/or family (by physician or nurse) regarding worsening
of symptoms and when to call the physician.
eight counseling May include any or all of the following elements:
● Verbal/written instructions regarding how to monitor/record daily weight
● Target weight
● Instructions on using a scale
● Instructions on what to do when weight increases, including parameters for seeking immediate help
● Written weight record
● Daily self-assessment for edema
● Counseling regarding fluid restriction
iet counseling pertinent to
owering cardiovascular risk
Advice given or discussion carried out with the patient and/or family regarding diet counseling. May include:
● Sodium restriction
● Fluid restriction
● Other (specify)
ounseling about alcohol
bstinence/restriction
Advice given or discussion carried out with the patient and/or family regarding the importance of abstaining
from or reducing intake of alcohol (43,44).
ctivity counseling Advice given or discussion carried out with the patient and/or family regarding activity level and restrictions
in activity, and/or exercise recommendations.
moking cessation counseling Advice given or discussion carried out with the patient (by physician, nurse, or other personnel) regarding the
importance of stopping smoking. May include:
● Counseling (may be basic or advanced)
● Written materials
● Referral to smoking cessation program
● Nicotine replacement therapy
mmunization counseling Advice given or discussion carried out with the patient and/or family regarding the importance of obtainingedicat
struct
etary
unde
cohol
tivity
lf-mo
lf-moations.
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mproving health status, decreasing patients’ symptoms, and
mproving function and quality of life are primary goals for
F treatment and represent important outcomes for HF
are. The Institute of Medicine, in Crossing the Quality
hasm (45), calls for a fundamental restructuring of the
ntire American health care system to establish a greater
ocus on optimizing patient-centered outcomes such as
ealth status. It follows that systematic assessment using
alidated instruments should be incorporated into prospec-
ive clinical trials, into quality assessment registries, and
ltimately insinuated throughout the process of HF care.
lthough such systematic assessment is not currently part of
outine clinical practice, an overview of health status assess-
ent is included in this clinical data standards document so that
uture applications may be more easily served.
For clinicians and others who are interested in systemat-
cally assessing the health status of their HF patients, several
hoices for measures exist (32,46). They fall into three
eneral types: single-item summary measures; generic
ealth status measures; and disease-specific instruments.
ingle-item summary measures are simple and quick to use,
ut they provide few details about the components of
atients’ health status, may not be reproducible, and could
able 10 Continued
Data Element
eferral
eferral to dietician for diet
ounseling
Referral to dietitian for weight
eferral to cardiac rehabilitation
rogram
Referral to cardiac rehabilitation
lan for follow-up care Documentation of plan for follo
Should include date of follow u
ollow-up visit Documentation of follow-up ev
● Patient history
● Functional status
● Physical examination
● Laboratory or other tests
Note date of follow-up visit.
atient referral Patient referred to other care:
● Heart failure specialty clinic
● Heart failure transitional car
● Heart failure disease manag
● Evaluation for heart transpla
Transitional care (specify durati
● Home health care
● Heart failure nurse case man
● Hospice or palliative care
● Home telemonitoring
● Ambulatory cardiac telemetr
Period of time enrolled in progr
success/participation in the progave limited sensitivity to important clinical change. peneric measures allow comparison across disease states,
nd capture the health status limitations of co-morbid
onditions. Because these measures may be influenced by
actors other than patients’ HF status, they may lack the
eproducibility and sensitivity to changes in HF status
esired for many of the applications anticipated in this
ocument. Information gleaned using disease-specific mea-
ures is directly relevant to HF care, and is generally more
linically interpretable, more reliable, and more sensitive to
linical change than other assessment techniques. An over-
iew of various instruments for each of these assessment
echniques is provided in Table A1.
There is some lack of clarity with regard to the domains
f health status that are being quantified with specific
nstruments. In fact, authors frequently use the words
symptoms,” “function,” “functional status,” “quality of life,”
nd “health status” interchangeably. Figure A1 is designed
o provide a framework of the different components of
ealth status (used to represent the total of patients’ expe-
iences of symptoms, function, and quality of life). Modified
rom the concept of Wilson and Cleary (47) for patients
ith HF (48), it describes the underlying disease process of
eft ventricular dysfunction and neurohormonal imbalance
hat is manifested in patients as symptoms of fatigue,
dema, and dyspnea. These symptoms can, in turn, affect
Definition
ement and/or advanced nutritional instruction.
ther structured exercise program.
care with physician and/or nurse.
n for patients with established heart failure should include:
advanced practice nurses
program
nitoring (e.g., mobile cardiac outpatient telemetry)
nd/or qualitative characterization of level of patient’s
) may be specified.manag
or o
w-up
p.
aluatio
e by
ement
nt
on):
ager
ic mo
am a
ram(satients’ physical, emotional, cognitive, and social function.
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Assessment Instrument
Self-
Administered
Number of
Items Domains Comments
. Disease Specific Measures for Heart Failure
hronic Heart Failure
Questionnaire (49)
No Variable ● Dyspnea during daily activities
● Fatigue
● Emotional function
Interviewer-administered
ansas City Cardiomyopathy
Questionnaire (32)
Yes 23 ● Physical limitation
● Symptoms (frequency, severity
and recent change)
● Quality of life
● Social function
● Self-efficacy
● Summary scores
More recent instrument with less published
experience than other measures
innesota Living with Heart
Failure Questionnaire (50)
Yes 21 ● Physical
● Emotional
● Total–quality of life
Used in many previous clinical trials
ew York Heart Association
Classification (30)
No Variable ● Physical limitation and
symptoms are assessed by a
clinician and assigned a score of
I–IV
Most commonly used measure of functional
status; however, a coarse measure from the
physician’s rather than the patient’s point of
view
. Generic Health Status Measures
uroQol (51) Yes 6 ● Mobility
● Self-care
● Usual activities
● Pain/discomfort
● Anxiety/depression
Can be converted into a health utility
measure
ottingham Health Profile (52) Yes 38 ● Sleep
● Pain
● Emotional reactions
● Social isolation
● Physical mobility
● Energy level
uality of Well-Being Scale (53) No 38 ● Mobility
● Physical activity
● Symptoms/problems
Can be converted into a health utility
measure
F-12 (21) Yes 12 ● Physical Component Score
● Mental Component Score
Less response burden than SF-36; however,
provides only summary measures of physical
and mental function
F-36 (54) Yes 36 ● Physical functioning
● Role–emotional
● Mental health
● Role–physical
● Bodily pain
● General health
● Vitality
● Social functioning
Most frequently used health status measure
ickness Impact Profile (55) Yes 136 ● Activities of daily living
including physical and
psychosocial interactions
Documented validity, reliability, and
sensitivity; frequently used; however,
significant response burden
. Single-Item Rating Scales
lobal Assessment (56) Yes 1 Generally a 5-point Likert scale
rating current health or change in
health
Simple; however, validity, reliability and
responsiveness may be poor. The greater
the duration of time that a global health
assessment of change is supposed to
quantify, the poorer the validity.
ingle-item Visual Analogue
Scale (57,58)
Yes 1 Generally rates current health
along a continuum of death to
perfect health
Simple; however, can be difficult to score,
may not be reliable or sufficiently valid
A
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